SynthesisJNCI cancer spectrum2026

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis.

Yu Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.